Pancreatic Cancer
Conditions
Keywords
Ablative Irradiation, 18-090
Brief summary
This study is being done to test whether receiving a dose of radiation that is higher than the standard dose, in combination with chemotherapy, improves the chance of becoming a candidate for surgery and improves the chance of extending the patient's life.
Interventions
RADIATIONHypofractionated ablative IMRT (HFA-IMRT)
total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions
DRUGcapecitabine
Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This phase II trial.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytopathologically confirmed adenocarcinoma of the pancreas. * Locally advanced, unresectable pancreatic cancer defined on post-induction chemotherapy CT as having tumor involvement of \>180° (\> 50%) of the circumference of the superior mesenteric artery (SMA) or celiac axis, unreconstructable superior mesenteric vein (SMV) or PV involvement. * No evidence of distant metastasis either prior to or after induction chemotherapy. * Completion of at least 3 months of standard induction chemotherapy for LAPC, which may include FOLFIRINOX or gemcitabine and nab-paclitaxel, within 6 weeks of enrollment. * For patients currently receiving investigational agents, a washout of at least 2 weeks or 5 half-lives of experimental agent are required prior to the start of RT. * Age ≥18 years. * KPS 70-100. * Patients must have acceptable organ and marrow function as defined below: * Leukocytes \>3,000/µL * Absolute neutrophil count \>1,500/µL * Platelets \>75,000/µL * Total bilirubin Within 2 x upper limit of normal * AST (SGOT)/ALT (SGPT) \<2.5 x institutional upper limit of normal Creatinine Within 1.5 x upper limit of normal, OR Creatinine clearance \>60 mL/min for patients with creatinine levels above institutional normal * Any systemic therapy associated toxicity should be Grade 1 or less * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* Patients who have borderline resectable disease using NCCN definition. * Patients who have had prior abdominal radiotherapy. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia. * Patients who are not surgical candidates due to medical co-morbidities. * Patients in whom iodine contrast is contraindicated. * Pregnant and breastfeeding women are excluded. Women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to 4 weeks after the study are excluded. This applies to any woman who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months, or women on hormone replacement therapy with serum FSH levels greater than 35 mIU/mL. A negative serum pregnancy test must be obtained within 14 days prior to the start of study therapy in all women of child-bearing potential. Male subjects must also agree to use effective contraception for the same period as above.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of patients who undergo definitive surgery | 2 years | The proportion of patients who undergo definitive surgery will be used to evaluate efficacy of HFA-IMRT in improving rates of resectability as compared to historical controls. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMarsha Reyngold
Memorial Sloan Kettering Cancer Center
Outcome results
None listed